Europe

The plausibility battleground at the EPO

Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.

• A stricter interpretation: the EPO and antibodies 27-10-2020
• Why Santen ends Neurim-style SPCs 25-08-2020
• How patents for transgenic mice got caught in a sufficiency trap 16-07-2020
• EPO’s G3/19: no turning back? 02-07-2020
• Analysis: Kymab’s ‘patent bargain’ clarification and why it matters 25-06-2020

More europe features